LifeMine Therapeutics: Funding, Investors & Team (Sep 2026)
LifeMine Therapeutics combines genomics with AI and synthetic biology to discover and develop a pipeline of novel medicines. LifeMine’s Avatar-Rx platform integrates high-throughput microbiology, data science and machine learning, genome engineering, and automation technologies to search the fungal biosphere for novel GEMs having a predetermined target and biological function. The platform integrates chemoinformatic-assisted drug optimization and state-of-the-art chemical synthesis with biotransformation to advance new product candidates into development. Founded by Gregory Verdine, PhD, Rick Klausner, MD, and WeiQing Zhou, MBA. LifeMine Therapeutics is headquartered in Cambridge, Massachusetts.
LifeMine Therapeutics has raised $413M across 3 funding rounds on record, the most recent a Series E of $188M announced in Aug 2026.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
LifeMine Therapeutics Company Profile and Key Stats
Latest funding round on record: Aug 2026.
LifeMine Therapeutics Funding Rounds
LifeMine Therapeutics raised $50.0M in a Series B announced in Jan 2021.
1.2 years later, a Series C of $175M was announced in Mar 2022.
4.4 years later, a Series E of $188M was announced in Aug 2026.
LifeMine Therapeutics Investors
18 investors are recorded in total; the 5 named above are those the record identifies.
LifeMine Therapeutics Founders and Leadership Team
Contact details for the LifeMine Therapeutics team: 3 of 3 have an email address on file, 2 have a LinkedIn profile.
Start 14-day free trial →LifeMine Therapeutics Funding Compared to Other Biotechnology Startups
LifeMine Therapeutics' latest round of $188M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like LifeMine Therapeutics in Biotechnology and Cambridge
Companies Similar to LifeMine Therapeutics
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
LifeMine Therapeutics Funding FAQs
What does LifeMine Therapeutics do?
LifeMine Therapeutics combines genomics with AI and synthetic biology to discover and develop a pipeline of novel medicines. LifeMine’s Avatar-Rx platform integrates high-throughput microbiology, data science and machine learning, genome engineering, and automation technologies to search the fungal biosphere for novel GEMs having a predetermined target and biological function. The platform integrates chemoinformatic-assisted drug optimization and state-of-the-art chemical synthesis with biotransformation to advance new product candidates into development. Founded by Gregory Verdine, PhD, Rick Klausner, MD, and WeiQing Zhou, MBA. LifeMine Therapeutics is headquartered in Cambridge, Massachusetts.
How much funding has LifeMine Therapeutics raised?
LifeMine Therapeutics has raised $413M across 3 rounds on record. The most recent is a Series E of $188M announced in Aug 2026.
When did LifeMine Therapeutics last raise funding?
LifeMine Therapeutics' most recent funding round on record is a Series E of $188M, announced in Aug 2026.
Who has invested in LifeMine Therapeutics?
Investors on record for LifeMine Therapeutics include RA Capital Management, ARCH Venture Partners, Invus, Fidelity, Foresite Capital. FundedIQ records 18 investors in total.
Who founded LifeMine Therapeutics?
FundedIQ lists Weiqing Zhou (Co-founder & Chief Operating Officer) at LifeMine Therapeutics.
Who is the CEO of LifeMine Therapeutics?
Greg Verdine is listed as CEO at LifeMine Therapeutics.
Where is LifeMine Therapeutics headquartered?
LifeMine Therapeutics is based in Cambridge, Massachusetts, United States.
How many employees does LifeMine Therapeutics have?
LifeMine Therapeutics is in the 101-250 employee band.
When was LifeMine Therapeutics founded?
LifeMine Therapeutics was founded in 2016.
How does LifeMine Therapeutics' funding compare to other Biotechnology startups?
LifeMine Therapeutics' latest round of $188M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's LifeMine Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for LifeMine Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.